Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory ...

U.S. health officials have asked doctors to prioritize which infants get the new RSV shot, just as cases of the respiratory disease begin to rise with the onset of cold and flu season. Due to a ...

Add Yahoo as a preferred source to see more of our stories on Google. The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -The U.S. Food and Drug ...

Add Yahoo as a preferred source to see more of our stories on Google. A wall showing a Merck & Co. logo in Kenilworth, New Jersey (Courtesy of Merck & Co.) This story was originally published on ...

Credit: Getty Images. The BLA acceptance was supported by data from the randomized, placebo-controlled phase 2b/3 CLEVER trial as well as interim data from the ongoing phase 3 SMART trial. A ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

The Advisory Committee on Immunization Practices recommended clesrovimab for infants under eight months old born during or entering their first RSV season. Clesrovimab adds to existing RSV prevention ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV ...